{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    10,
    11,
    12,
    26,
    28,
    29,
    33,
    34,
    35,
    36,
    37,
    41,
    42,
    43,
    50
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Exploratory Substudy Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2.6",
        "sectionTitle": "Exploratory Substudy",
        "description": "Reference to language allowing Sponsor to propose exploratory substudies."
      },
      {
        "id": "ref_2",
        "name": "Sample Size Rationale",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1.1",
        "sectionTitle": "Overview of Study Design",
        "description": "Reference to study design overview regarding sample size increase."
      },
      {
        "id": "ref_3",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 1",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference for missed PK, PD, or ADA samples and general study activities."
      },
      {
        "id": "ref_4",
        "name": "IMP Transit Monitoring",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.3.3",
        "sectionTitle": "Investigational Medicinal Product Transit",
        "description": "Reference to temperature and time monitoring for drug transit."
      },
      {
        "id": "ref_5",
        "name": "Visual Functioning Questionnaire",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.5.8.1",
        "sectionTitle": "NEI VFQ-25 Administration",
        "description": "Clarification on the administration of the NEI VFQ-25."
      },
      {
        "id": "ref_6",
        "name": "Medical Monitor Contacts",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.4.1",
        "sectionTitle": "Medical Monitor and Emergency Medical Contacts",
        "description": "Reference to updated contact information."
      },
      {
        "id": "ref_7",
        "name": "Pregnancy Notification",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.4.3.1",
        "sectionTitle": "Pregnancy Notification",
        "description": "Reference to Informed Consent Form instructions for female patients."
      },
      {
        "id": "ref_8",
        "name": "Safety Population Clarification",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.2.5",
        "sectionTitle": "Safety Population",
        "description": "Clarification on the faricimab-pooled safety population."
      },
      {
        "id": "ref_9",
        "name": "Immunogenicity Analysis",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.2.7",
        "sectionTitle": "Immunogenicity Analysis Population",
        "description": "Clarification on the immunogenicity analysis population."
      },
      {
        "id": "ref_10",
        "name": "Data Sharing Policy",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.6",
        "sectionTitle": "Dissemination of Data and Protection of Trade Secrets",
        "description": "Correction of the Roche policy name on data sharing."
      },
      {
        "id": "ref_11",
        "name": "Questionnaire Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 10",
        "sectionTitle": "National Eye Institute 25-Item Visual Functioning Questionnaire",
        "description": "Reference to updated and added pages for NEI VFQ-25."
      },
      {
        "id": "ref_12",
        "name": "Study Eye Eligibility",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1.1.2",
        "sectionTitle": "Study Eye Eligibility Criteria",
        "description": "Definition of macular edema due to BRVO."
      },
      {
        "id": "ref_13",
        "name": "Study Treatment Details",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.3.1",
        "sectionTitle": "Study Treatment",
        "description": "Details on faricimab, aflibercept, or sham procedure."
      },
      {
        "id": "ref_14",
        "name": "Visual Acuity Assessment",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.5.5",
        "sectionTitle": "Visual Acuity",
        "description": "Reference to ETDRS visual acuity chart testing."
      },
      {
        "id": "ref_15",
        "name": "PTI Dosing Criteria",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1.4.1",
        "sectionTitle": "PTI Dosing Criteria",
        "description": "Criteria for personalized treatment interval dosing."
      },
      {
        "id": "ref_16",
        "name": "Masking Details",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.2.2",
        "sectionTitle": "Masking",
        "description": "Details on masking requirements and unmasked investigators."
      },
      {
        "id": "ref_17",
        "name": "Eligibility Criteria",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Reference to patient eligibility requirements."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Substantive new information appears in italics.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Protocol Amendment Rationale",
        "pageNumber": 4
      },
      {
        "id": "annot_2",
        "text": "This amendment represents cumulative changes to the original protocol.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Protocol Amendment Rationale",
        "pageNumber": 4
      },
      {
        "id": "annot_3",
        "text": "The investigator will determine unilateral versus bilateral disease status at screening.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Screening",
        "pageNumber": 36
      },
      {
        "id": "annot_4",
        "text": "IVT = intravitreal; PTI = personalized treatment interval; Q4W = every 4 weeks; W = Week.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Study Schema",
        "pageNumber": 35
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "1",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-04-03",
        "description": "Original Protocol",
        "amendmentNumber": "0"
      },
      {
        "id": "ver_2",
        "versionNumber": "2",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-11-17",
        "description": "Protocol Amendment 2: Primary change to increase patient sample size and allow exploratory substudies.",
        "amendmentNumber": "Amendment 1"
      }
    ],
    "summary": {
      "referenceCount": 17,
      "annotationCount": 4,
      "versionCount": 2
    }
  }
}